Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled?

被引:4
作者
Brockstein, B [1 ]
机构
[1] Northwestern Univ, Sch Med, Dept Med, Evanston NW Healthcare, Evanston, IL 60201 USA
关键词
D O I
10.1097/00001622-200005000-00007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chemotherapy has become integrated into the treatment of head and neck cancer in not only the palliative but now also the primary setting. Organ preservation is possible using induction chemotherapy, and improved survival results have been confirmed for concomitant chemoradiotherapy. The taxanes, paclitaxel and docetaxel, appear to be as active as any other drugs in head and neck cancer. When used in combination in the induction, recurrent, or metastatic settings, response rates rival those of the standard cisplatin/5-fluorouracil regimen. At least one ongoing study will help to establish superiority of cisplatin/paclitaxel versus cisplatin/5-fluorouracil in the recurrent or metastatic setting, and another between cisplatin/5-fluorouracil and doctaxel/cisplatin/5-fluorouracil in the induction setting. Both paclitaxel and docetaxel are being extensively studied as radiosensitizers. They are relatively well tolerated and have good efficacy but have not yet been adequately studied in comparison with other regimens. In conclusion, the taxanes have significantly expanded our effective treatment options in both the primary and recurrent or metastatic settings. Curr Opin Oncol 2000, 12:221-228 (C) 2000 Lippincott Williams & Wilkins, Inc.
引用
收藏
页码:221 / 228
页数:8
相关论文
共 68 条
[11]   RANDOMIZED COMPARISON OF CISPLATIN, METHOTREXATE, BLEOMYCIN AND VINCRISTINE (CABO) VERSUS CISPLATIN AND 5-FLUOROURACIL (CF) VERSUS CISPLATIN (C) IN RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A PHASE-III STUDY OF THE EORTC HEAD AND NECK-CANCER COOPERATIVE GROUP [J].
CLAVEL, M ;
VERMORKEN, JB ;
COGNETTI, F ;
CAPPELAERE, P ;
DEMULDER, PHM ;
SCHORNAGEL, JH ;
TUENI, EA ;
VERWEIJ, J ;
WILDIERS, J ;
CLERICO, M ;
DALESIO, O ;
KIRKPATRICK, A ;
SNOW, GB .
ANNALS OF ONCOLOGY, 1994, 5 (06) :521-526
[12]   Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial [J].
Colevas, AD ;
Busse, PM ;
Norris, CM ;
Fried, M ;
Tishler, RB ;
Poulin, M ;
Fabian, RL ;
Fitzgerald, TJ ;
Dreyfuss, A ;
Peters, ES ;
Adak, S ;
Costello, R ;
Barton, JJ ;
Posner, MR .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1331-1339
[13]   Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck [J].
Colevas, AD ;
Norris, CM ;
Tishler, RB ;
Fried, MP ;
Gomolin, HI ;
Amrein, P ;
Nixon, A ;
Lamb, C ;
Costello, R ;
Barton, J ;
Read, R ;
Adak, S ;
Posner, MR .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3503-3511
[14]   A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck [J].
Couteau, C ;
Chouaki, N ;
Leyvraz, S ;
Oulid-Aissa, D ;
Lebecq, A ;
Domenge, C ;
Groult, V ;
Bordessoule, S ;
Janot, F ;
De Forni, M ;
Armand, JP .
BRITISH JOURNAL OF CANCER, 1999, 81 (03) :457-462
[15]  
DANG TP, 1999, P AM SOC CLIN ONCOL, V18, pA401
[16]  
*DAT INC, 2000, SINGL AG CHEM HEAD N
[17]   RANDOMIZED TRIAL OF NEOADJUVANT CISPLATIN AND FLUOROURACIL VERSUS CARBOPLATIN AND FLUOROURACIL IN PATIENTS WITH STAGE IV-M0 HEAD AND NECK-CANCER [J].
DEANDRES, L ;
BRUNET, J ;
LOPEZPOUSA, A ;
BURGUES, J ;
VEGA, M ;
TABERNERO, JM ;
MESIA, R ;
LOPEZ, JJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1493-1500
[18]  
Dowell JE, 1999, SEMIN RADIAT ONCOL, V9, P97
[19]   Docetaxel: An active drug for squamous cell carcinoma of the head and neck [J].
Dreyfuss, AI ;
Clerk, JR ;
Norris, CM ;
Rossi, RM ;
Lucarini, JW ;
Busse, PM ;
Poulin, MD ;
Thornhill, L ;
Costello, R ;
Posner, MR .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1672-1678
[20]  
DUFFY K, 1999, P AM SOC CLIN ONCOL, V18, pA401